A Swiss CBD company claims to have become the first cannabidiol firm to use liposomes to deliver the substance into users’ bodies.
Cibdol, based in Liestal, near Basel, says its range of products, launched in December, will enter the user’s system as much as four times quicker than traditional oils and capsules.
Liposomes, which have most notably been used for some cancer treatments, are microscopic pockets made from the same material as cell membranes which can be filled with medicines, drugs, and vitamins.
Because they are made from a substance extensively found in cells – phospholipids – they penetrate directly into tissue and cell walls, and can pass directly into a patient’s bloodstream.
CBD-Intel provides premium market and regulatory analysis, legal tracking, and quantitative data for the cannabidiol (CBD) sectors, with a focus on non-US markets.
We provide our clients with the tools to navigate this fast-moving sector, tailor their business strategy, optimise resources and make informed decisions.